Blockchain Registration Transaction Record

Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs

Clene (NASDAQ: CLNN) releases Q2 2024 financial results and provides updates on CNM-Au8(R) programs for treating ALS and Rett Syndrome. The company's potential new drug application offers hope to patients with critical time needs.

Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results and Updates on CNM-Au8(R) Programs

This news matters because Clene's potential new drug application could offer hope to patients with ALS and Rett Syndrome, addressing critical time needs for treatment.

BlockchainDetails
Contract Address0x0553B273B8eBf464Bd2a37C259F0eEBb3d70Fd71
Transaction ID0x4e15056ed67723f8dd2aacea3725502eb4482ae385c9e68225887d76e95d56dd
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital Fingerprintlushv7zt-02f503f5ad926c8424123084faea3c63